DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



MESS-study MRSA Eradication Study Skåne

Information source: Region Skane
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Throatcarriers of MRSA

Intervention: Mupirocin (Drug); Rifampin+Clindamycine or Trimehoprimsulfa (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Region Skane

Official(s) and/or principal investigator(s):
Eva Melander, MD PHD, Principal Investigator, Affiliation: Labmedicin Skåne Malmö

Overall contact:
Eva Melander, MD Phd, Phone: +4640-33 74 86, Email: eva.z.melander@skane.se

Summary

The purpose of this study is to determine whether systemic antibiotic treatment with rifampicin and clindamycine or trimethoprim-sulfa in addition to topical treatment with mupirocin is more effective than only topical treatment to eradicate MRSA in throatcarriers

Clinical Details

Official title: MESS- MRSA Eradication Study Skne. A Comparison Between Systemic Antibiotic Treatment in Combination With Topical Mupirocintreatment With Only Topical Mupiroicintreatment to Eradicate MRSA in Throat Carriers

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Culture for MRSA

Eligibility

Minimum age: 5 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: Colonized with MRSA in the throat Older than 5 years MRSA-bacteria sensitive for

Rifampicin and Clindamycine or Trimethoprimsulfa -

Exclusion Criteria: Allergy to the studymedication Healthcareworkers Pregnancy Active infection with MRSA Immunosuppression Treatment with other antibiotic during the studyperiod

Locations and Contacts

Eva Melander, MD Phd, Phone: +4640-33 74 86, Email: eva.z.melander@skane.se

Karolinska university hospital, Stockholm, Sweden; Completed

Örebro university hospital, Örebro, Sweden; Completed

Helsingborg hospital, Helsingborg, Skåne, Sweden; Completed

Kristianstad hospital, Kristianstad, Skåne, Sweden; Completed

Infectious department SUS Lund, Lund, Skåne, Sweden; Completed

SUS Malmö, Malmö, Skåne, Sweden; Recruiting
Anna Nilsson, MD PhD, Email: anna.nilsson@med.lu.se
Anna Nilsson, MD, PhD, Principal Investigator

Additional Information

Starting date: March 2011
Last updated: May 25, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017